Last reviewed · How we verify

Scemblix (ASCIMINIB HYDROCHLORIDE)

Novartis · FDA-approved approved Small molecule Quality 60/100

Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms.

Scemblix (Asciminib hydrochloride) is a small molecule therapy originally developed by Novartis and currently owned by the same company. It targets the Tyrosine-protein kinase ABL1, a specific enzyme involved in the growth and survival of cancer cells. Scemblix is FDA-approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). The drug has a half-life of 5.5 hours and is patented, with no generic manufacturers available. Key safety considerations include its potential effects on the liver and blood cells.

At a glance

Generic nameASCIMINIB HYDROCHLORIDE
SponsorNovartis
TargetABL1 kinase of BCR::ABL1
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval2021

Mechanism of action

Asciminib works by targeting a specific part of the BCR::ABL1 fusion protein called the ABL myristoyl pocket. By binding to this site, it blocks the protein's ability to activate signaling pathways that promote cancer cell growth, effectively inhibiting both wild-type and mutant forms of BCR::ABL1.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: